Ipca Laboratories Ltd - IPCA LABS. Share Price

Sector: Pharmaceuticals | ISIN: INE571A01038
₹ 714.20 (1.23%) icon2 Jun, 2023, 3:54:45 PM
Open
₹ 705.50
Prev. Close
₹ 705.50
Turnover(lac)
₹ 4,595.11
Day's High
₹ 717.00
Day's Low
₹ 703.00
52 Wk High
₹ 1,034.30
52 Wk Low
₹ 669.80
Book Value
₹ 237.64
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 18,119.56
P/E
35.79
EPS
19.93
Div. Yield
0.00

Ipca Laboratories Ltd Stock View

info icon
Edit Image
Target | 26 Apr, 2023 856.762 (19.96%)

Ipca Laboratories Limited is an India-based pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (A... Read More

Ipca Laboratories Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 6/2/2023 3:54:45 PM

    ₹ 714.2 8.70 1.23
  • Open
  • ₹ 705.5
  • Prev. Close
  • ₹ 705.5
  • Turnover(Lac.)
  • ₹ 4,595
  • Day's High
  • ₹ 717
  • Day's Low
  • ₹ 703
  • 52 Week's High
  • ₹ 1,034.3
  • 52 Week's Low
  • ₹ 669.8
  • Book Value
  • ₹ 237.64
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 18,119.56
  • P/E
  • 35.79
  • EPS
  • 19.93
  • Divi. Yield
  • 0

Ipca Laboratories Ltd Corporate Actions

12 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

24 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Jan , 2023

12:00 AM

11 Nov , 2022

12:00 AM

Dividend

Dividend amount: 4
Announcement date: 11 Nov , 2022

View Details

02 Nov , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 Nov , 2022

12:00 AM

20 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

28 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

14 Jul , 2022

12:00 AM

AGM

Announcement date: 14 Jul , 2022

View Details

28 Jul , 2022

12:00 AM

14 Jul , 2022

12:00 AM

BookCloser

View Details

Ipca Laboratories Ltd SHAREHOLDING SNAPSHOT
03 June , 2023 | 11:10 PM

PROMOTER - TOTAL46.29%

Indian: 46.29%

Foreign: 0%

NON-PROMOTER - TOTAL 53.71%

Institutions: 44.64%

Non-Institutions: 9.07%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Ipca Laboratories Ltd News and Update

Image not found
  • 1 day ago |
  • 5:44 PM

According to Aditya Birla Capital Ltd., the preferential issuance would take place at a cost of Rs 165.1 per equity share and is pending approval from shareholders.

Image not found
Image not found
  • IIFL News Service |
  • 29 May, 2023 |
  • 5:39 PM
Article Image
  • IIFL News Service |
  • 25 May, 2023 |
  • 5:32 PM
ad IconAd Image

Ipca Laboratories Ltd FINANCIALS

Ipca Laboratories Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Ipca Laboratories Ltd

  • Premchand Godha
  • Chairman & MD & CEO
  • A K Jain
  • Joint Managing Director & CFO
  • Anand T Kusre
  • Independent Director
  • Pranay Godha
  • Executive Director
  • Harish P Kamath
  • Company Secretary
  • Prashant Godha
  • Executive Director
  • Manisha Premnath
  • Independent Director
  • Kamal Kishore Seth
  • Independent Director
  • Narendra Mairpady
  • Additional Director

Summary

Ipca Laboratories Limited (IPCA) was incorporated on 19th October, 1949 under the name of The Indian Pharmaceutical Combine Association Limited. Ipca is a fully integrated, pharmaceutical company manufacturing and marketing over 350 formulations and 80 APIs covering various therapeutic segments. The products of the Company are now sold in over 100 countries across the globe. The Company has 17 manufacturing units in India manufacturing APIs and formulations for the world market.Ipcas APIs and Formulations produced at world class manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA) with operations in over 100 countries. Ipca is one of the biggest manufacturers in the world of APIs Atenolol (Antihypertensive), Chloroquine Phosphate (Antimalarial), Furosemide (Diuretic) and Pyrantel Salts (Anthelmintic) right from the basic stage. Ipca is also one of the largest suppliers of these APIs and their intermediates world over. The name of the company was changed to Ipca Laboratories Limited in 6th August of the year 1964 and again name was changed to Ipca Laboratories Private Limited in 13th January of the year 1966. Ipca had commissioned one of the first modern Pharma factory of yesteryears... Read More


Reports by Ipca Laboratories Ltd


Reports by Ipca Laboratories Ltd